Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
Shirish M. Gadgeel, Leena Gandhi, Gregory J. Riely et al. · The Lancet Oncology · 2014
Cited by 698 works. doi:10.1016/s1470-2045(14)70362-6
Authors
- Shirish M. Gadgeel
- Leena Gandhi
- Gregory J. Riely
- Alberto Chiappori
- Howard West
- Michele C. Azada
- Peter N. Morcos
- Ruey-min Lee
- Linta Garcia
- Li J. Yu
- Frédéric Boisserie
- Laura Di Laurenzio
- Sophie Golding
- Jotaro Sato
- Tomohiro Tanaka
- Sai‐Hong Ignatius Ou
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
- Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
- Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer